Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000077.xml
Download PDF
Semin Thromb Hemost 2001; 27(4): 405-416
DOI: 10.1055/s-2001-16893
DOI: 10.1055/s-2001-16893
Recombinant Antithrombin: Production and Role in Cardiovascular Disorder
Further Information
Publication History
Publication Date:
31 August 2001 (online)
ABSTRACT
Plasma-derived antithrombin (AT) concentrates have been used for the management of hereditary and acquired deficiencies since the early 1980s. Recombinant versions of other blood factors and their derivatives are increasingly becoming available, providing a safe and abundant supply of these important therapeutics. However, the complexity of the AT molecule and the large doses often required for supplementation treatments preclude the use of traditional cell culture bioreactors for recombinant production. The development of a very efficient expression system has been necessary for the cost-efficient recombinant production of AT. Transgenic production, with its ability to yield high levels of heterologous protein and its scale-up flexibility, is an attractive alternative to plasma fractionation. Purification of recombinant AT from the milk of transgenic dairy goats has been developed to provide a homogeneous, well-defined, and abundant supply of this factor. This article describes the production of recombinant AT and aspects of clinical applications of this molecule to cardiovascular disorders.
KEYWORD
Recombinant antithrombin - transgenic production - cardiopulmonary bypass - heparin resistance - clinical trials
REFERENCES
- 1 Abildgaard U. Binding of thrombin to antithrombin III. Scand J Clin Lab Invest . 1969; 24 23-27
- 2 Yin E T, Wessler S, Stoll P J. Identity of plasma-activated factor X inhibitor with antithrombin 3 and heparin cofactor. J Biol Chem . 1971; 246 3712-4719
- 3 Rosenberg R D, Damus P S. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem . 1973; 248 6490-6505
- 4 Rosenberg J S, McKenna P, Rosenberg R D. Inhibition of human factor IXa by human antithrombin-heparin cofactor. J Biol Chem . 1975; 248 8883-8889
- 5 Kurachi K, Fujikawa, Schmer G, Davie E W. Inhibition of bovine factor IXa and factor Xa by antithrombin III. Biochemistry . 1976; 15 373-377
- 6 Stead N, Kaplan A P, Rosenberg R D. Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem . 1976; 251 6481-6488
- 7 Kondo S, Kisiel W. Regulation of factor VIIa activity in plasma: evidence that antithrombin III is the sole plasma protease inhibitor of human factor VIIa. Thromb Res . 1987; 46 325-335
- 8 Blajchman M A, Austin R, Fernandez-Rachubinski F, Sheffield W P. Molecular basis of an inherited human antithrombin deficiency. Blood . 1992; 80 2159-2171
- 9 Andersson L-O, Engman L, Henningson E. Crossed immunoelectrophoresis applied to studies on complex formation. The binding of heparin to antithrombin III and the antithrombin-thrombin complex. J Immunol Methods . 1977; 14 271-281
- 10 Perlmutter D H, Glover G I, Rivertna M. Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc Natl Acad Sci USA . 1990; 87 3753-3757
- 11 Pizzo S V. Serpin receptor 1: a hepatic receptor that mediates the clearance of antithrombin III-proteinase complexes. Am J Med . 1989; 87(Suppl 3B) 10S-14S
- 12 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh . 1965; 13 516-530
- 13 Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol . 1981; 10 369-390
- 14 Hirsh J, Piovella F, Pini M. Congenital antithrombin III deficiency. Am J Med . 1989; 87(Suppl 3B) 34S-8S
- 15 Lechner K, Kyrle P A. Antithrombin III concentrates-are they clinically useful?. Thromb Haemost . 1995; 73 340-348
- 16 van Boven H H, Lane D A. Antithrombin and its inherited states. Semin Hematol . 1997; 34 188-204
- 17 Büller H R, ten Cate W J. Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate. Am J Med . 1989; 87(3B) 44S-48S
- 18 Mammen E F. Clinical relevance of antithrombin deficiencies. Semin Thromb Haemost . 1995; 32 2-6
- 19 Baker Jr F W, Bick R L. Treatment of hereditary and acquired thrombophilic disorders. Semin Thromb Hemost . 1999; 25 387-406
- 20 Smith-Erichsen N, Aasen A O, Gallimore M J, Amundsen E. Studies of components of the coagulation systems in normal individuals and septic shock patients. Circ Shock . 1982; 9 491-497
- 21 Wilson R F, Farag A, Mammen E F, Fujii Y. Sepsis and antithrombin III, prekallikrein, and fibronectin levels in surgical patients. Am Surg . 1989; 55 450-456
- 22 Fourrier F, Chopin C, Goudemand J. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest . 1992; 101 816-823
- 23 Wilson R F, Mammen E F, Tyburski J G, Warsow K M, Kubinec S M. Antithrombin levels related to infections and outcome. J Trauma . 1996; 40 384-387
- 24 Owings J T, Bagley M, Gosselin R, Romac D, Disbrow E. Effect of critical injury on plasma antithrombin activity: low antithrombin levels are associated with thromboembolic complications. J Trauma . 1996; 41 396-405
- 25 Blauhut B, Necek S, Vinazzer H, Bergmann H. Substitution therapy with an antithrombin III concentrate in shock and DIC. Thromb Res . 1982; 27 271-278
- 26 Vinazzer H. Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation. Semin Thromb Hemost . 1989; 15 347-352
- 27 Menache D, O'Malley J P, Schorr J B. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative Study Group. Blood . 1990; 75 33-39
- 28 Fourrier F, Chopin C, Huart J J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest . 1993; 104 882-888
- 29 Haire W D. Antithrombin III in hematopoietic stem cell transplantation. Semin Thromb Hemost . 1997; 23 591-601
- 30 Balk R, Emerson T, Fourrier F. Therapeutic use of antithrombin concentrate in sepsis. Semin Thromb Hemost . 1998; 24 183-194
- 31 Bucur S Z, Levy J H, Despotis G J, Spiess B D, Hillyer C D. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion . 1998; 38 481-498
- 32 Eisele B, Lamy M, Thijs L G. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med . 1998; 24 663-672
- 33 Kanbak M. The treatment of heparin resistance with antithrombin III in cardiac surgery. Can J Anaesth . 1999; 46 581-585
- 34 Nakabayashi M, Asami M, Nakatani A. Efficacy of antithrombin replacement therapy in severe early-onset preeclampsia. Semin Thromb Hemost . 1999; 25 463-466
- 35 Vinazzer H. Hereditary and acquired antithrombin deficiency. Semin Thromb Hemost . 1999; 25 257-263
- 36 Williams M R, D'Ambra A B, Beck J R. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg . 2000; 70 873-877
- 37 Houdebine L M. The production of pharmaceutical proteins from the milk of transgenic animals. Reprod Nutr Dev . 1995; 35 609-617
- 38 Echelard Y. Recombinant protein production in transgenic animals. Curr Opin Biotechol . 1996; 7 536-540
- 39 Meade H M, Echelard Y, Ziomek C A. Expression of recombinant proteins in the milk of transgenic animals. In: Fernandez JM, Hoeffler JP, eds. Gene Expression Systems: Using Nature for the
Art of Expression, San Diego, CA: Academic Press; 1999: 399-427
MissingFormLabel
- 40 Clark A J. The mammary gland as a bioreactor: expression, processing, and production of recombinant proteins. J Mammary Gland Biol Neopl . 1998; 3 337-350
- 41 Ebert K M, DiTullio P, Barry C A. Induction of human tissue plasminogen activator in the mammary gland of transgenic goats. Biotechnology . 1994; 12 699-702
- 42 Edmunds T, Van Patten M S, Pollock J. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood . 1998; 91 4561-4571
- 43 Pollock D P, Kutzko J P, Birck-Wilson E. Transgenic milk as a method for the production of recombinant antibodies. J Immunol Methods . 1999; 231 147-157
- 44 Roberts B, DiTullio P, Vitale J, Hehir K, Gordon K. Cloning of the goat beta-casein-encoding gene and expression in transgenic mice. Gene . 1992; 121 255-262
- 45 Zettlmeissl G, Conradt H S, Nimtz M, Haigwood N, Paques E P. Influence of glycosylation on the functional properties of human therapeutic plasma proteins. GBF Monogr Ser . 1991; 15 259-275
- 46 Olson S T, Frances-Chmura A, Swanson R, Bjork I, Zettlmeissl G. Effect of individual carbohydrate chains of recombinant antithrombin on heparin affinity. Arch Biochem Biophys . 1997; 341 212-221
- 47 Garone L, Edmunds T, Hanson E. Antithrombin-heparin affinity reduced by fucosylation of carbohydrate at asparagine 155. Biochemistry . 1996; 35 8881-8889
- 48 Minnema M C, Chang A C, Jansen P M. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli Blood . 2000; 95 1117-1123
- 49 Taylor Jr B F, Emerson Jr E T, Jordan R, Chang A K, Blick K E. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock . 1988; 26 227-235
- 50 Yamauchi T, Umeda F, Inoguchi T, Nawata H. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun . 1989; 163 1404-1411
- 51 Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res . 1990; 59 895-904
- 52 Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Effects of antithrombin III (AT III) and Trp49-modified AT III on plasma level of 6-keto-PGF1 alpha in rats. Thromb Res . 1995; 80 201-208
- 53 Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol . 1996; 270 L921-L930
- 54 Ostrovsky L, Woodman R C, Payne D, Teoh D, Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation . 1997; 96 2302-2310
- 55 Fourrier F, Jourdain M, Tournoys A. Effects of a combined antithrombin III and protein C supplementation in porcine acute endotoxic shock. Shock . 1998; 10 364-370
- 56 Inthorn D, Hoffmann J N, Hartl W H, Muhlbayer D, Jochum M. Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock . 1998; 10 90-96
- 57 Dickneite G, Leithauser B. Influence of antithrombin III on coagulation and inflammation in porcine septic shock. Arterioscler Thromb Vasc Biol . 1999; 19 1566-1572
- 58 Hoffmann J N, Vollmar B, Inthorn D, Schildberg F W, Menger M D. Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway. Am J Physiol . 2000; 279 C98-C107
- 59 Okajima K, Uchiba M. The anti-inflammatory properties of antithrombin III: new therapeutic implications. Semin Thromb Hemost . 1998; 24 27-32
- 60 Dickneite G. Antithrombin III in animal models of sepsis and organ failure. Semin Thromb Hemost . 1998; 24 61-69
- 61 Neviere R, Tournoys A, Mordon S. Antithrombin III reduces mesenteric venule leukocyte adhesion and small intestine injury in endotoxemic rats. Shock . 2001; 15 220-225
- 62 Bachmann F, McKenna R, Cole E R, Najafi H. The hemostatic mechanism after open heart surgery: I. Studies on plasma coagulation factors and fibrinolysis in 512 patients after extracorporeal circulation. J Thorac Cardiovasc Surg . 1975; 70 76-85
- 63 Colman R W. Surface mediated defense reactions. The plasma contact activation system. J Clin Invest . 1984; 73 1249-1253
- 64 Kluft C, Dooijewaard G, Emeis J J. Role of the contact system in fibrinolysis. Semin Thromb Hemost . 1987; 13 50-68
- 65 Woodman R C, Harker L A. Bleeding complications associated with cardiopulmonary bypass. Blood . 1990; 76 1680-1697
- 66 Furie B, Furie B C. Molecular and cellular biology of blood coagulation. N Engl J Med . 1992; 326 800-806
- 67 Davie E W, Ratnoff O D. Waterfall sequence for intrinsic blood clotting. Science . 1964; 145 1310
- 68 Vasalli J D, Sappino A P, Belin D. The plasminogen activator/plasmin system. J Clin Invest . 1991; 88 1067-1072
- 69 Ogston D, Ogston C M, Ratnoff O D, Forbes C D. Studies on a complex mechanism for the activation of plasminogen by kaolin and chloroform: the participation of Hageman factor and additional cofactors. J Clin Invest . 1969; 48 1786-1801
- 70 Levin E G, Marzec U, Anderson J, Harker L A. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest . 1984; 74 1988-1995
- 71 Ranby M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochem Biophys Acta . 1982; 704 461-469
- 72 Bick R L. The clinical significance of fibrinogen degradation products. Semin Thromb Hemost . 1982; 8 302-330
- 73 Slaughter T F. The coagulation system and cardiac surgery. In: Estafanous FG, Barash PG, Reves JG, eds. Cardiac Anesthesia: Principles and Clinical
Practice, Vol 24 1994: 621-633
MissingFormLabel
- 74 Senning A. Plasma-heparin concentration in extracorporeal circulation. Acta Chir Scand . 1959; 117 55-59
- 75 Akl B F, Vargas G M, Neal J, Robillard J, Kelly P. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass. J Thorac Cardiovasc Surg . 1980; 79 97-102
- 76 Culliford A T, Gitel S N, Starr N. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg . 1981; 193 105-111
- 77 Esposito R A, Culliford A T, Colvin S B. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass. J Thorac Cardiovasc Surg . 1983; 85 174-185
- 78 Gravlee G P, Haddon W S, Rothberger H K. Heparin dosing and monitoring for cardiopulmonary bypass. J Thorac Cardiovasc Surg . 1990; 99 518-527
- 79 Horkay F, Martin P, Rajah S M, Walker D R. Response to heparinization in adults and children undergoing cardiac operations. Ann Thorac Surg . 1992; 53 822-826
- 80 Hattersley P G. Activated coagulation time of whole blood. JAMA . 1967; 196 436-440
- 81 Bull B S, Korpeman R A, Heise W M, Briggs B D. Heparin therapy during extracorporeal circulation. I. Problems in existing heparin protocols. J Thorac Cardiovasc Surg . 1975; 69 674-684
- 82 Bull B S, Huse W M, Brauer F S, Korpeman R A. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg . 1975; 69 685-689
- 83 Babka R, Colby C, El-Etr A, Pifarre R. Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery. J Thorac Cardiovasc Surg . 1977; 73 780-782
- 84 Horrow J C. Heparin reversal of protamine toxicity: Have we come full circle?. J Cardiothorac Anesth . 1990; 4 539-542
- 85 Pifarre R, Babka R, Sullivan H J. Management of postop heparin rebound following cardiopulmonary bypass. J Thorac Cardiovasc Surg . 1981; 81 378-381
- 86 Verska J J. Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis. Ann Thorac Surg . 1977; 24 170-173
- 87 Hill J D, Dontigny L, de Leval M. A simple method of heparin management during prolonged extracorporeal circulation. Ann Thorac Surg . 1974; 17 129-134
- 88 Metz S, Keats A S. Low activated clotting time does not increase postoperative bleeding. Ann Thorac Surg . 1990; 49 440-444
- 89 Brister S J, Ofosu F A, Buchanan M R. Thrombin generation during cardiac surgery: Is heparin the ideal anticoagulant?. Thromb Haemost . 1993; 70 259-262
- 90 Slaughter T F, LeBleu T H, Douglas Jr M J. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology . 1994; 80 520-526
- 91 Boisclair M D, Lane D A, Philippou H. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood . 1993; 82 3350-3357
- 92 Smith R C, Leung J M, Mangano D T, SPI Research Group. Postoperative myocardial ischemia in patients undergoing coronary bypass graft surgery. Anesthesiology . 1991; 74 464-473
- 93 Ponari O, Corsi M, Manotti C. Predictive value of in vitro and in vivo studies for correct individual heparinization in cardiac surgery. J Thorac Pathol Cardiovasc Surg . 1979; 78 87-94
- 94 Miller W M, Binford J M, Hessel E A. Results of a survey of the professional activities of 811 cardiopulmonary perfusionists. J Thorac Cardiovasc Surg . 1982; 83 385-389
- 95 Soloway H B, Christiansen T W. Heparin anticoagulation during cardiac surgery in an AT-III deficient patient. Am J Clin Pathol . 1980; 73 723-725
- 96 Chung F, David T E, Watt J. Excessive requirement for heparin during cardiac surgery. Can Anaesth Soc J . 1981; 28 280-282
- 97 Hanowell S T, Kim Y D, Rattan V, MacNamara T E. Increased heparin requirement with hypereosinophilic syndrome. Anesthesiology . 1981; 55 450
- 98 Mabry C D, Read R C, Thompson B W, Williams G D, White H J. Identification of heparin resistance during cardiac and vascular surgery. Arch Surg . 1979; 114 128-135
- 99 Staples M H, Dunton R F, Karlson K J, Leonardi H K, Berger R L. Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping. Ann Thorac Surg . 1994; 57 1211-1216
- 100 Dietrich W, Spannagl, Schramm W. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass. J Thorac Cardiovasc Surg . 1991; 102 505-514
- 101 Cloyd G M, D'Ambra M N, Akins C W. Diminished anticoagulant response to heparin in patients undergoing coronary bypass grafting. J Thorac Cardiovasc Surg . 1987; 94 535-538
- 102 Marciniak E, Gockerman J P. Heparin-induced decrease in circulating antithrombin-III. Lancet . 1977; 2 581-584
- 103 Addonizio V P, Fisher C A, Kappa J R, Ellison N. Prevention of heparin-induced thrombocytopenia during open heart surgery with iloprost (ZK 36374). Surgery . 1987; 102 796-807
- 104 Kappa R, Fisher C, Berkowitz H D, Cottrell E D, Addonizio V P. Heparin induced platelet activation in sixteen surgical patients: diagnosis and management. J Vasc Surg . 1987; 5 101-109
- 105 Cornad J, LeCompte T, Horellon M H, Cazenave B, Sanama M. AT III in patients treated with subcutaneous or intravenous heparin. Thromb Res . 1981; 22 507-511
- 106 Sabbagh A H, Chung G KT, Shuttleworth P, Applegate B J, Gabriel W. Fresh frozen plasma: a solution to heparin resistance during cardiopulmonary bypass. Ann Thorac Surg . 1984; 37 466-468
- 107 Barnette R E, Shupak R C, Pontius J, Rao A K. In vitro effect of fresh frozen plasma on the activated coagulation time in patients undergoing cardiopulmonary bypass. Anesth Analg . 1988; 67 57-60
- 108 Dietrich W, Schroll A, Barankay A, Richter J A. Effect of antithrombin III substitution on heparin response during extracorporeal circulation. Anesthesiology . 1985; 63 3A Abstract
- 109 Hashimoto K, Yamagishi M, Sasaki T, Nakano M, Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass correlation with subclinical plasma coagulation. Ann Thorac Surg . 1994; 58 799-804
- 110 Zaidan J R, Johnson S, Byrnes R, Monroe S, Guffin A V. Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary artery surgery. Anesth Analg . 1986; 65 377-380
- 111 Levy J H, Montes F, Szlam F, Hillyer C D. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg . 2000; 90 1076-1079
- 112 Despotis G J, Levine V, Joist J H, Joiner-Maier D, Spitznagel E. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Anesth Analg . 1997; 85 498-506
- 113 Rihal C S, Flather M, Hirsh J, Yusuf S. Advances in antithrombotic drug therapy for coronary artery disease. Eur Heart J . 1995; 16S 10-21
- 114 Yue R H, Gertler M M, Starr T, Koutrouby R. Alteration of plasma antithrombin III levels in ischemic heart disease. Thromb Haemost . 1976; 35 598-606
- 115 Losito R, Gattiker H, Bilodeau G, Longpre B. Natural coagulation inhibitors: an assessment in patients. Ann NY Acad Sci . 1981; 370 714-719
- 116 Vaziri N D, Kennedy S C, Kennedy D, Gonzales E. Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction and angina pectoris. Am J Med . 1994; 96 651-657
- 117 Granger C B, Miller J M, Bovill E G. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation . 1995; 91 1929-1935
- 118 Lidon R M, Theroux P, Robitaille D. Antithrombin III plasma activity during and after prolonged use of heparin in unstable angina. Thromb Res . 1993; 72 23-32
- 119 Biasucci L M, Liuzzo G, Caligiuri G. Temporal relation between ischemic episodes and activation of the coagulation system in unstable angina. Circulation . 1996; 93 2121-2127
- 120 Merlini P A, Ardissino D, Bauer K A. Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol . 1997; 17 1325-1330
- 121 Grip L, Blombäck M, Egberg N. Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study. Eur Heart J . 1997; 18 443-449
- 122 Lu W, Mant T, Levy J H, Bailey J M. Pharmacokinetics of recombinant transgenic antithrombin in volunteers. Anesth Analg . 2000; 90 531-534
- 123 Levy J H, Despotis G J, Olson P J, Weisinger A, Szlam F. Transgenically produced recombinant human ATIII enhances the antithrombotic effects of heparin in patients undergoing cardiac surgery. Blood . 1997; 90(Suppl I) 298A Abstract